View Author
trapidil ultrasound intravascular stent patient intravascular ultrasound follow-up volume restenosi lumen diameter trial study lumen diameter month angiography placebo eur heart j table neointimal group in-stent angioplasty implantation in-stent neointimal volume heart 6 months balloon angioplasty angiographic balloon wallstent length event luminal serruy lesion trial medication placebo group randomized artery stenting issue result factor outcome end-point lumen area medication october population ----= trapidil group target lesion revascularization intention-to-treat trapist feyter luminal diameter md phd netherland imputation circulation hospital wallstent implantation growth stent implantation rotterdam 1 month analysis disease anginal vessel compliance hyperplasia post-stenting feyter pj in-stent restenosis proliferative process effect muscle cells trapidil group stent area
2 Most Recent Publications
|
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
(Article)
Serruys, P.W.J.C. Foley, D.P. Pieper, M. Kleijne, J.A. Feyter, P.J. de |
2002-07-01
|
|
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound.
(Article)
Serruys, P.W.J.C. Foley, D.P. Pieper, M. Kleijne, J.A. Feyter, P.J. de |
2001-11-24
|
